Renalytix AI plc (RNLX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
RNLX Chart
Renalytix shares gain as billable test numbers set new company record
Renalytix PLC (AIM:RENX) shares moved up on Thursday thanks to an upbeat trading update, revealing a 20% rise in third-quarter revenue. The company, which specialises in artificial intelligence-enabled in vitro diagnostics, told investors it processed more than 1,000 billable kidneyintelX.dkd tests in the quarter.
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno'), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices.
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”
Renalytix AI plc Dividends
Renalytix AI plc Earnings
| 13 Dec 2024 Date | | - Cons. EPS | - EPS |
| 26 Sep 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
| 22 Apr 2024 Date | | - Cons. EPS | - EPS |
| 15 Feb 2024 Date | | - Cons. EPS | - EPS |
| 13 Dec 2024 Date | | - Cons. EPS | - EPS |
| 26 Sep 2024 Date | | - Cons. EPS | - EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
| 22 Apr 2024 Date | | - Cons. EPS | - EPS |
| 15 Feb 2024 Date | | - Cons. EPS | - EPS |
Renalytix AI plc (RNLX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Renalytix AI plc ever had a stock split?
Renalytix AI plc Profile
| Health Information Services Industry | Healthcare Sector | Mr. James R. McCullough M.B.A. CEO | NASDAQ (NMS) Exchange | US75973T1016 ISIN |
| US Country | - Employees | - Last Dividend | - Last Split | 17 Jul 2020 IPO Date |
Overview
Renalytix Plc, established in 2018 and headquartered in New York, New York, is at the forefront of developing artificial intelligence-enabled in vitro diagnostic solutions specifically targeting kidney diseases. Through a blend of AI technology, clinical insights, and partnerships, it aims to revolutionize the diagnosis, prognosis, and treatment of kidney diseases. Initially known as Renalytix AI plc, the company transitioned to Renalytix Plc in June 2021 to better reflect its broadened scope and commitment to kidney disease diagnostics. By leveraging strategic partnerships with entities such as Mount Sinai Health System, Joslin Diabetes Center, Inc., Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine, Renalytix Plc is enhancing the kidney health care model through advanced diagnostics and clinical care solutions.
Products and Services
- KidneyIntelX
The flagship product of Renalytix Plc, KidneyIntelX, stands as a testament to the innovation in kidney disease diagnostics. This diagnostic platform incorporates an artificial intelligence-enabled algorithm that assimilates diverse data inputs. These inputs include validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health records. The integration of these varied data points results in the generation of a unique patient risk score. This risk score plays a critical role in the diagnosis and prognosis of kidney disease, guiding clinical care, stratifying patients for drug clinical trials, and discovering new targets for kidney disease treatment. The development and commercialization of KidneyIntelX are empowered by a license agreement with Mount Sinai Health System, facilitating the application of artificial intelligence in the realm of kidney disease diagnosis.
Contact Information
